Apollon, a developer of noninvasive continuous glucose monitoring (CGM) technology, has been selected for the Massachusetts eHealth Institute (MeHI) Digital Health Sandbox program, a key state initiative designed to support real-world clinical validation of innovative medical technologies and accelerate their commercialization.
Through this selection, Apollon will receive full funding for approximately $50,000 of clinical trials conducted at the MIT Center for Clinical & Translational Research. This is a significant example of a Korean startup securing direct funding from a U.S. state government.
The MeHI Sandbox Program operates as a competitive selection process that allows early-stage startups to build testbeds, conduct clinical trials, and conduct user studies without financial burden. Key evaluation criteria include the potential to create tangible value within the U.S. healthcare system, the contribution to improving health equity, and the impact on strengthening the state's industrial ecosystem.
With this support, Apollon plans to verify the accuracy and safety of its Raman-based non-invasive CGM technology and actively pursue regulatory and clinical strategies for entry into the US market. The company anticipates that this will allow it to offer new innovations to the global CGM market, which has traditionally relied on invasive technologies.
Hong A-ram, CEO of Apollo, said, “This achievement goes beyond simply securing subsidies; it is a recognition of the social and national need for non-invasive CGM technology.”
- See more related articles
You must be logged in to post a comment.